ADMA Biologics
ADMA
95 hedge funds and large institutions have $88.8M invested in ADMA Biologics in 2020 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 18 closing their positions.
57% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 23
6% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 18
0% more funds holding
Funds holding: 95 → 95 (0)
5.8% less ownership
Funds ownership: 53.54% → 47.75% (-5.8%)
30% less capital inflows, than outflows
Capital inflows: $6.55M | Capital outflows: $9.37M
44% less call options, than puts
Call options by funds: $1.15M | Put options by funds: $2.08M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$791K |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$731K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$695K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$557K |
| 5 |
Magnetar Financial
Evanston,
Illinois
|
+$419K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.58M |
| 2 |
MFAM
Motley Fool Asset Management
Alexandria,
Virginia
|
-$1.6M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.06M |
| 4 |
Goldman Sachs
New York
|
-$688K |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$478K |
ADMA Hedge Fund Activity: Q4 2020 in Review
95 of the 5,678 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q4 2020, worth a combined $88.8M — down 20% from $110M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ADMA positions and 18 closed out — a net gain of 1 holder — while 36 added to existing stakes and 23 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $791K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $2.58M sold.
- 95 institutional investors held ADMA Biologics (ADMA) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $88.8M of ADMA Biologics stock for Q4 2020, down 20% quarter-over-quarter.
- 19 funds opened new ADMA Biologics positions in Q4 2020 and 18 closed out, a net change of +1 holder.
- The largest ADMA Biologics buyer in Q4 2020 was J. Goldman & Co, an estimated $791K added.
- The largest ADMA Biologics seller in Q4 2020 was Sphera Funds Management, an estimated $2.58M sold.
Based on aggregated 13F filings for Q4 2020.